Pfizer is making a $500M statement today: Here’s how you become a lead player in the booming gene therapy sector
Three years ago, Pfizer anted up $150 million in cash to buy Bamboo Therapeutics in Chapel Hill, NC as it cautiously stuck a toe in the small gene therapy pool of research and development.
Company execs followed up a year later with a $100 million expansion of the manufacturing operations they picked up in that deal for the UNC spinout, which came with $495 million in milestones.
And now they’re really going for it.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,700+ biopharma pros reading Endpoints daily — and it's free.